"Antitubercular Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy.
| Descriptor ID |
D000995
|
| MeSH Number(s) |
D27.505.954.122.085.255
|
| Concept/Terms |
Antitubercular Agents- Antitubercular Agents
- Agents, Antitubercular
- Antitubercular Drugs
- Drugs, Antitubercular
- Tuberculostatic Agents
- Agents, Tuberculostatic
|
Below are MeSH descriptors whose meaning is more general than "Antitubercular Agents".
Below are MeSH descriptors whose meaning is more specific than "Antitubercular Agents".
This graph shows the total number of publications written about "Antitubercular Agents" by people in this website by year, and whether "Antitubercular Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 2 | 3 |
| 1997 | 1 | 2 | 3 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 2 | 0 | 2 |
| 2002 | 5 | 1 | 6 |
| 2003 | 0 | 1 | 1 |
| 2004 | 3 | 2 | 5 |
| 2005 | 2 | 1 | 3 |
| 2006 | 2 | 1 | 3 |
| 2007 | 2 | 0 | 2 |
| 2008 | 3 | 1 | 4 |
| 2009 | 2 | 4 | 6 |
| 2010 | 2 | 2 | 4 |
| 2011 | 7 | 3 | 10 |
| 2012 | 3 | 5 | 8 |
| 2013 | 5 | 4 | 9 |
| 2014 | 1 | 5 | 6 |
| 2015 | 3 | 2 | 5 |
| 2016 | 8 | 8 | 16 |
| 2017 | 7 | 0 | 7 |
| 2018 | 10 | 4 | 14 |
| 2019 | 9 | 4 | 13 |
| 2020 | 7 | 5 | 12 |
| 2021 | 1 | 4 | 5 |
| 2022 | 1 | 4 | 5 |
| 2023 | 0 | 5 | 5 |
| 2024 | 5 | 3 | 8 |
| 2025 | 8 | 3 | 11 |
| 2026 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antitubercular Agents" by people in Profiles.
-
Costs of TB preventive treatment: insights from five sub-Saharan African countries. Int J Tuberc Lung Dis. 2026 Oct 30; 30(11):504-510.
-
Global burden of drug-resistant tuberculosis in children: a systematic analysis for the Global Burden of Disease Study. Eur Respir J. 2026 Oct; 68(4).
-
Duration of effectiveness of tuberculosis preventive treatment across various tuberculosis burden settings: a systematic review and individual-participant meta-analysis. Lancet Respir Med. 2026 Nov; 14(11):947-956.
-
Single-step Sintered 3D-printed Fixed-dose Combined?Bilayer Tablets for Compartmentalized Delivery of First-line Anti-tubercular Drugs. AAPS J. 2026 Sep 08; 28(5).
-
PD-L1-centric whole blood-based immune signature profiles of tuberculosis patients during therapy. Front Immunol. 2026; 17:1829438.
-
Targeted next-generation sequencing implementation in Eswatini identifies rifampicin and bedaquiline resistance undetected by routine diagnostic testing. Nat Commun. 2026 Jun 11; 17(1).
-
HIV-associated drug-resistant TB: expanded treatment options and emerging threats. Curr Opin HIV AIDS. 2026 Mar 01; 21(2):172-179.
-
Application of FreezeTB, a targeted nanopore sequencing assay, for identification of drug resistance and lineages among pulmonary tuberculosis cases in Alaska. Microbiol Spectr. 2026 01 06; 14(1):e0233525.
-
In-Silico Exploration of the StreptomeDB Database for Potential Irreversible DprE1 Inhibitors toward Antitubercular Treatment. ChemistryOpen. 2025 11; 14(11):e202500237.
-
Decentralising TB diagnosis and contact management: impact on detection and preventive treatment in children. Int J Tuberc Lung Dis. 2025 Jun 27; 29(7):312-317.